ElectroCore, Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year of 2022
January 17, 2023 at 06:30 pm IST
Share
electroCore, Inc. provided preliminary earnings guidance for the fourth quarter and full year of 2022. For the year, the company anticipates reporting record full year 2022 revenue of approximately $8.5 million. This would represent approximately 57% growth over full-year 2021 revenue of $5.5 million.
For the quarter, the company's revenue is anticipated to be approximately $2.5 million, which would represent approximately 68% growth over fourth quarter of 2021.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company. It provides non-invasive vagus nerve stimulation (nVNS) technology platform. The Companyâs product categories include Handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headache, and Handheld, personal use consumer products utilizing nVNS technology to promote general wellness and human performance. Its products include gammaCore, Truvaga and TAC-STIM. Its gammaCore Sapphire, is a prescription medical device that is used for a variety of primary headache conditions. Its Truvaga is a personal use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com. The Companyâs TAC-STIM product is not a medical device and is not intended to diagnose, cure, mitigate, prevent, or treat a disease or condition.